Resultado de búsqueda
Lars Iversen (Professor, MD, DMSc) joined MC2 Therapeutics from a position as Chair Professor of Dermatology at Aarhus University Hospital and has substantial experience within the field of dermatology in general, and in inflammatory and autoimmune skin diseases in particular.
Secukinumab was superior to nb-UVB in treating patients with new-onset moderate to severe plaque psoriasis. The high and sustained skin clearance observed indicates that biologic treatment for psoriasis may be more effective if used early in the disease course.
Professor Lars Iversen has been an IPC Councilor since 2009 and a Board Member of the IPC since 2017. He is a Professor in Dermatology at the University of Aarhus, Denmark, where he also teaches dermato-venereology.
Lars Iversen. Chair professor in dermatology, DMSc. Professor, Department of Clinical Medicine - The Department of Dermatology and Venereology. https://orcid.org/0000-0003-1816-4508. Email lars.iversen @ clin.au. dk. Palle Juul-Jensens Boulevard 45. 8200 Aarhus N.
2017. Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2 …. K Reich, RB...
9 de jun. de 2022 · Professor Lars Iversen will be a key member of the Executive Team at MC2 Therapeutics. He will be responsible for continued high quality in the strategy, direction, and execution of the...
6 de ene. de 2023 · Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study - Iversen - 2023 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library.
